SCHEMBL3143472

SCHEMBL3143472

CCC(Nc1ccc(O)c(F)c1)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SHBG P04278 1/20 0.42
EGLN1 Q9GZT9 1/20 0.39
FOLH1 Q04609 1/20 0.39
CYP17A1 P05093 1/20 0.39
KDM4E B2RXH2 2/20 0.39
GAA P10253 2/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ALB P02768 1/20 0.37
IL2 P60568 1/20 0.37
LMNA P02545 1/20 0.37
HSD17B10 Q99714 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
ALDH1A1 P00352 1/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2283372 0.86 GAA (0.42) KDM4EGAAMAPTMAPK1RAB9A
SCHEMBL3134935 0.83 GAA (0.45) KDM4EGAAMAPTMAPK1RAB9A
SCHEMBL5029423 0.81 TSHR (0.56) KDM4EGAAMAPTMAPK1RAB9A
SCHEMBL3134906 0.78 EGLN1 (0.38) SHBGEGLN1FOLH1CYP17A1ALB
SCHEMBL3143705 0.77 ALB (0.43) SHBGEGLN1FOLH1CYP17A1ALB
SCHEMBL3142287 0.75 ALDH1A1 (0.49) KDM4EGAAMAPTMAPK1RAB9A
SCHEMBL734621 0.75 CYP3A4 (0.53) KDM4EGAAMAPTMAPK1RAB9A
SCHEMBL5342232 0.74 RAB9A (0.50) KDM4EGAAMAPTMAPK1RAB9A
SCHEMBL5377321 0.74 RAB9A (0.50) KDM4EGAAMAPTMAPK1RAB9A
SCHEMBL5342235 0.74 RAB9A (0.50) KDM4EGAAMAPTMAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236826-B2 Diarylether derivatives as antitumor agents OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-08-07 US disclosed
US-8188277-B2 Aromatic compounds for suppressing the generation of collagen OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-05-29 US disclosed
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-01-07 US disclosed
US-20070270422-A1 Aromatic Compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS ROS1, CBR1, CBR3 SHBG 4748/4885EGLN1 1539/4885FOLH1 2675/4885
US-20070270422-A1 Aromatic Compounds COL1A1, COL2A1, COL14A1 SHBG 579/4885EGLN1 448/4885FOLH1 3994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.